Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease
- PMID: 12656907
- DOI: 10.1046/j.1464-410x.2003.04134.x
Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease
Abstract
Objective: To assess the effectiveness of the combination of colchicine and vitamin E (which has anti-fibrotic, anti-mitotic and anti-inflammatory effects) in modifying the early stages of Peyronie's disease, by evaluating pain relief, correction of deformities and plaque size.
Patients and methods: In all, 45 patients were divided into two groups and treated from January 1998 to November 2001. Their mean (range) age was 53.4 (40-62) years, the time from onset of the disease < 6 months and they had penile deformity of < 30 degrees; no patient had erectile dysfunction. Twenty-two patients were given ibuprofen 400 mg/day for 6 months, whilst 23 received a combination of vitamin E 600 mg/day plus colchicine 1 mg every 12 h. Pain, plaque size and penile deformity were assessed at 6 months.
Results: There were no statistically significant differences between the groups at baseline in age, time from onset of the disease until the initial evaluation or plaque size. Although the proportion of patients reporting pain relief was higher amongst those receiving colchicine plus vitamin E (91% vs 68%) this was not significantly different, but differences in plaque size and penile curvature were significant.
Conclusions: The use of colchicine plus vitamin E during the early stages of Peyronie's disease (time from onset < 6 months) in patients with penile curvature of < 30 degrees and no erectile dysfunction is an effective and well-tolerated way to stabilize the disease. A more extensive study is needed, comparing these results with other oral therapies.
Similar articles
-
Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease.J La State Med Soc. 2001 Jul;153(7):358-63. J La State Med Soc. 2001. PMID: 11519219 Clinical Trial.
-
Evaluation of penile hemodynamic status and adjustment of treatment alternatives in Peyronie's disease.Asian J Androl. 2002 Sep;4(3):187-90. Asian J Androl. 2002. PMID: 12364974 Clinical Trial.
-
Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome.Int J Impot Res. 2000 Jun;12(3):169-75. doi: 10.1038/sj.ijir.3900519. Int J Impot Res. 2000. PMID: 11045911
-
Management of Peyronie's disease--a review.World J Urol. 2001 Aug;19(4):244-50. World J Urol. 2001. PMID: 11550782 Review.
-
Pharmacological Management of Peyronie's Disease.Drugs. 2007;67(4):527-45. doi: 10.2165/00003495-200767040-00004. Drugs. 2007. PMID: 17352513 Review.
Cited by
-
Non-surgical therapies for Peyronie's disease.Cochrane Database Syst Rev. 2023 Jul 17;7(7):CD012206. doi: 10.1002/14651858.CD012206.pub2. Cochrane Database Syst Rev. 2023. PMID: 37490423 Free PMC article. Review.
-
A systematic review of non-surgical management in Peyronie's disease.Int J Impot Res. 2023 Sep;35(6):523-532. doi: 10.1038/s41443-022-00633-w. Epub 2022 Oct 26. Int J Impot Res. 2023. PMID: 36289392 Free PMC article. Review.
-
Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database.Int J Impot Res. 2022 Apr;34(3):280-288. doi: 10.1038/s41443-021-00430-x. Epub 2021 Apr 7. Int J Impot Res. 2022. PMID: 33828265 Free PMC article.
-
Minimally invasive therapies for Peyronie's disease: the current state of the art.Transl Androl Urol. 2020 Mar;9(Suppl 2):S269-S283. doi: 10.21037/tau.2019.08.06. Transl Androl Urol. 2020. PMID: 32257868 Free PMC article. Review.
-
Medical Management of Peyronie's Disease: Review of the Clinical Evidence.Med Sci (Basel). 2019 Sep 18;7(9):96. doi: 10.3390/medsci7090096. Med Sci (Basel). 2019. PMID: 31540526 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical